This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Idalopirdine
- DrugBank Accession Number
- DB11957
- Background
Idalopirdine has been used in trials studying the treatment of Cognition, Schizophrenia, and Alzheimer's Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Idalopirdine (DB11957)
- Weight
- Average: 398.377
Monoisotopic: 398.141754055 - Chemical Formula
- C20H19F5N2O
- Synonyms
- Idalopirdine
- External IDs
- LU AE-58054
- LU AE58054
- LU-AE-58054
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Idalopirdine is combined with 1,2-Benzodiazepine. Acenocoumarol The risk or severity of adverse effects can be increased when Idalopirdine is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Idalopirdine. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Idalopirdine. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Idalopirdine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Idalopirdine. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Idalopirdine. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Idalopirdine. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Idalopirdine. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Idalopirdine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Idalopirdine Hydrochloride 545BT5182Y 467458-02-2 KXOQNPANAFXKTN-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Tryptamines and derivatives
- Direct Parent
- Tryptamines and derivatives
- Alternative Parents
- 3-alkylindoles / Phenylmethylamines / Phenoxy compounds / Phenol ethers / Benzylamines / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Aryl fluorides / Heteroaromatic compounds show 5 more
- Substituents
- 3-alkylindole / Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 59WCJ0YNWM
- CAS number
- 467459-31-0
- InChI Key
- YBAWYTYNMZWMMJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2
- IUPAC Name
- [2-(6-fluoro-1H-indol-3-yl)ethyl]({[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl})amine
- SMILES
- FC(F)C(F)(F)COC1=CC=CC(CNCCC2=CNC3=CC(F)=CC=C23)=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 21071390
- PubChem Substance
- 347828282
- ChemSpider
- 19878969
- BindingDB
- 50019754
- ChEMBL
- CHEMBL3286580
- ZINC
- ZINC000095936819
- Wikipedia
- Idalopirdine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Alzheimer's Disease (AD) 4 2 Completed Treatment Alzheimer's Disease (AD) 1 2 Completed Treatment Cognitive Functioning / Schizophrenia 1 1 Completed Not Available Healthy Subjects (HS) 1 1 Completed Treatment Alzheimer's Disease (AD) 1 1 Completed Treatment Healthy Subjects (HS) 4 1 Completed Treatment Hepatic Impairment 1 1 Terminated Treatment Alzheimer's Disease (AD) 1 1 Withdrawn Treatment Bioequivalence 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00356 mg/mL ALOGPS logP 4.66 ALOGPS logP 4.8 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 16.75 Chemaxon pKa (Strongest Basic) 9.59 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 37.05 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 95.67 m3·mol-1 Chemaxon Polarizability 35.99 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:05 / Updated at February 21, 2021 18:53